Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| 0.7862 | |
| 0.7879 | |
| - | |
| 0.79 | |
| 0.77 | |
| 0.58-3.75 | |
| 88 437 K | |
| 115 M | |
| 0 | |
| -0.26 | |
| 0.768 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AlloVir, Inc. (ALVR) been one of those stocks this year? A qu...
A downtrend has been apparent in AlloVir, Inc. (ALVR) lately with too much selling pressure. The stock has declined 72.4% over the past four weeks. However, given the fact that it is now in oversold t...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
